Marshall Wace
MAZE

Marshall Wace’s Maze Therapeutics MAZE Stock Holding History

Marshall Wace’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.3M Buy
914,572
+603,933
+194% +$15.8M 0.02% 590
2026
Q1 		$9.27M Sell
310,639
-536,833
-63% -$23.7M 0.01% 1015
2025
Q4 		$35.1M Buy
847,472
+69,771
+9% +$2.4M 0.03% 447
2025
Q3 		$20.2M Buy
777,701
+758,104
+3,868% +$12.8M 0.02% 650
2025
Q2 		$240K Hold
19,597
– – ﹤0.01% 2400
2025
Q1 		$216K Buy
+19,597
New +$236K ﹤0.01% 2381

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

Marshall Wace's MAZE Position: Q2 2026 in Review

Marshall Wace increased its Maze Therapeutics (MAZE) stake by 194% in Q2 2026, buying an estimated $15.8M and bringing the position to 914,572 shares worth $27.3M. The position accounts for 0.02% of the portfolio, ranked #590.

Marshall Wace first reported a position in MAZE in Q1 2025 and has held it in 6 quarters since. The position peaked at $35.1M in Q4 2025. 162 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • Marshall Wace held 914,572 shares of Maze Therapeutics worth $27.3M as of Q2 2026.
  • Marshall Wace bought 603,933 Maze Therapeutics shares in Q2 2026, an estimated $15.8M.
  • Maze Therapeutics made up 0.02% of Marshall Wace's portfolio in Q2 2026, its #590 holding.
  • Marshall Wace first reported a position in Maze Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Marshall Wace's Maze Therapeutics position peaked at $35.1M in Q4 2025.
  • 162 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.